Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: Target trial emulation

Authors

• Yan Xie, Washington University School of Medicine in St. Louis
• Taeyoung Choi, Veterans Affairs Saint Louis Health Care System
• Ziyad Al-Aly, Washington University School of Medicine in St. Louis

Journal

BMJ Medicine

Publication Date

3-18-2026

Volume

5

Issue

1

First Page

e002150

Document Type

Open Access Publication

DOI

10.1136/bmjmed-2025-002150

Rights and Permissions

Xie Y, Choi T, Al-Aly Z. Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. BMJ Med. 2026 Mar 18;5(1):e002150. doi: 10.1136/bmjmed-2025-002150. Copyright © 2026, The Author(s). Published by BMJ Publishing Group Ltd. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license

Recommended Citation

Xie, Yan; Choi, Taeyoung; and Al-Aly, Ziyad, "Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: Target trial emulation." BMJ Medicine. 5, 1. e002150 (2026).
https://digitalcommons.wustl.edu/oa_4/7132

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.